CA2410512A1 - Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques - Google Patents

Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques Download PDF

Info

Publication number
CA2410512A1
CA2410512A1 CA002410512A CA2410512A CA2410512A1 CA 2410512 A1 CA2410512 A1 CA 2410512A1 CA 002410512 A CA002410512 A CA 002410512A CA 2410512 A CA2410512 A CA 2410512A CA 2410512 A1 CA2410512 A1 CA 2410512A1
Authority
CA
Canada
Prior art keywords
vector
raav
cytokine
gene
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002410512A
Other languages
English (en)
Inventor
Sergei Zolotukhin
Satya P. Kalra
Lyle L. Moldawer
Nicholas Muzyczka
William W. Hauswirth
Pushpa S. Kalra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2410512A1 publication Critical patent/CA2410512A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Abstract

La présente invention concerne des procédés se rapportant à l'utilisation de cytokine ou de polynucléotides codant la cytokine pour la création de cellules hôtes transformées et d'animaux transgéniques. L'invention concerne plus particulièrement l'utilisation de compositions à base de vecteur rAAV (virus adéno-associé recombinant) comprenant des séquences de polynucléotides exprimant au moins une cytokine mammalienne ou des polypeptides récepteurs de cytokine. L'invention concerne enfin des procédures applicables pour le traitement et l'amélioration des symptômes de divers états et troubles affectant l'animal, et notamment la cécité, la rétinite pigmentaire, la dégénérescence maculaire liée à l'âge, l'obésité, l'anorexie, et les troubles liés à l'alimentation, ainsi que des troubles neurologiques et musculo-squelettiques tels que la sclérose latérale amyotrophique.
CA002410512A 2000-06-09 2001-06-08 Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques Abandoned CA2410512A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59081000A 2000-06-09 2000-06-09
US09/590,810 2000-06-09
PCT/US2001/040901 WO2001094605A2 (fr) 2000-06-09 2001-06-08 Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
CA2410512A1 true CA2410512A1 (fr) 2001-12-13

Family

ID=24363808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002410512A Abandoned CA2410512A1 (fr) 2000-06-09 2001-06-08 Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques

Country Status (4)

Country Link
EP (1) EP1290206A2 (fr)
AU (1) AU2001267058A1 (fr)
CA (1) CA2410512A1 (fr)
WO (1) WO2001094605A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498964A (zh) * 2002-11-07 2004-05-26 本元正阳基因技术股份有限公司 可诱导RNAi途径的用于基因治疗的系列重组腺相关病毒
GB0327384D0 (en) * 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20080254451A1 (en) * 2004-12-28 2008-10-16 Ares Trading S.A. Compositions and Methods for Treating Schizophrenia and Related Disorders
WO2006096613A2 (fr) 2005-03-04 2006-09-14 Northwestern University Separation de nanotubes de carbone dans des gradients de densite
US20080217588A1 (en) 2006-08-30 2008-09-11 Arnold Michael S Monodisperse single-walled carbon nanotube populations and related methods for providing same
CA2704418A1 (fr) * 2007-10-30 2009-05-07 Neurologix, Inc. Nouvelle methode de therapie genique concernant le traitement de l'obesite liee a des troubles du metabolisme
JP5852969B2 (ja) 2010-02-26 2016-02-03 コーネル ユニヴァーシティー 人工網膜
US9309534B2 (en) 2010-07-12 2016-04-12 Universidad Autonoma De Barcelona Gene therapy composition for use in diabetes treatment
EP2611401A4 (fr) 2010-08-31 2014-03-19 Univ Cornell Prothèse rétinienne
US9302103B1 (en) 2010-09-10 2016-04-05 Cornell University Neurological prosthesis
KR101976048B1 (ko) 2011-08-25 2019-05-09 코넬 유니버시티 머신 비전용 망막 인코더
EP2692868A1 (fr) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Vecteurs viraux adéno-associés (AAV) utiles pour la transduction de tissu adipeux
CA2960912A1 (fr) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Vecteurs viraux adeno-associes pour la therapie genique des maladies metaboliques
CA2974235A1 (fr) 2015-01-07 2016-07-14 Universitat Autonoma De Barcelona Construction genique a vecteur unique comprenant des genes d'insuline et de glucokinase
EP3291780A4 (fr) 2015-04-20 2019-01-23 Cornell University Vision industrielle avec réduction de données dimensionnelles
WO2017060510A1 (fr) * 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la maladie d'alzheimer
CA3018224A1 (fr) * 2016-03-31 2017-10-05 University Of Cincinnati Methodes et compositions pour le traitement de la sla
RU2653487C1 (ru) * 2016-11-30 2018-05-08 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена lif и/или уменьшением количества белка фактора, ингибирующего лейкемию, на основе генно-терапевтических субстанций с геном lif, способ получения и использования
WO2020023621A1 (fr) * 2018-07-24 2020-01-30 Puneeth Iyengar Traitement amélioré de perte de poids
RU2720376C1 (ru) * 2018-11-29 2020-04-29 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов IL11, LIF, DICER, HOXA10, WT1, для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-IL11, или Escherichia coli SCS110-AF/VTvaf17-LIF, или Escherichia coli SCS110-AF/VTvaf17-DICER, или Escherichia coli SCS110-AF/VTvaf17-HOXA10, или Escherichia coli SCS110-AF/VTvaf17-WT1, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
RU2715314C1 (ru) * 2019-01-25 2020-02-26 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор VTvaf17-Act1-Cas9 на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген Cas9, для гетерологичной экспрессии этого целевого гена в клетках растений при геномном редактировании растений, способ получения и применения генотерапевтического ДНК-вектора, штамм Escherichia coli SCS110-AF/VTvaf17-Act1-Cas9, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
GB202202628D0 (en) * 2022-02-25 2022-04-13 Babraham Inst Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048806A1 (fr) * 1996-06-20 1997-12-24 Merck & Co., Inc. Therapie genique pour le traitement de l'obesite
US6521225B1 (en) * 1996-09-06 2003-02-18 Chiron Corporation AAV vectors
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU8672198A (en) * 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
PT1064393E (pt) * 1998-03-20 2005-04-29 Univ Pennsylvania Composicoes e metodos para a producao de virus adeno-associados recombinantes sem auxiliar

Also Published As

Publication number Publication date
WO2001094605A2 (fr) 2001-12-13
WO2001094605A3 (fr) 2002-12-05
AU2001267058A1 (en) 2001-12-17
EP1290206A2 (fr) 2003-03-12

Similar Documents

Publication Publication Date Title
CA2410512A1 (fr) Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques
US9023617B2 (en) Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
US20060078542A1 (en) Gel-based delivery of recombinant adeno-associated virus vectors
US7342111B2 (en) Adeno-associated virus-delivered ribozyme compositions and methods of use
EP0938553B1 (fr) Adn codant dp-75 et procede d'utilisation
US6696415B2 (en) Treatment of ocular neovascularization and related diseases
US20050271625A1 (en) RAAV-neprilysin compositions and methods of use
Kusano et al. Long-term stable expression of human growth hormone by rAAV promotes myocardial protection post-myocardial infarction
WO2000069454A1 (fr) Suppression de l'igfbp-2 endogene visant a inhiber le cancer
US20060281703A1 (en) Treatment of disease using an improved regulated expression system
AU768986B2 (en) IL-6/sIL-6R complex for promotion of liver functions
US11510999B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
US6534310B1 (en) Suppression of proteolytic activity by dysfunctional protease formation
US20090068147A1 (en) Raav vector-based pro-opiomelanocortin compositions and methods of use
WO1996014863A9 (fr) Suppression de l'activite proteolytique par formation de protease dysfonctionnelle
US20070179113A1 (en) GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20060292609A1 (en) Interferon-beta gene therapy using an improved, regulated expression system
Flannery et al. Ribozyme-mediated gene therapy for autosomal dominant retinal degeneration
Newbound et al. Repression of tax‐mediated human t‐lymphotropic virus type 1 transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear Cells
EP2137314B1 (fr) Nouvelles molécules modulatrices destinées à un système d'expression régulée amélioré
TW202235618A (zh) 治療眼內壓相關疾患
CA2275438A1 (fr) Methodes ameliorees de transduction cellulaire
WO1998022605A9 (fr) Methodes ameliorees de transduction cellulaire

Legal Events

Date Code Title Description
FZDE Dead